Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Sophie PeltekianShellyza SajwaniXiang WangSalmaan KanjiPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)
The incidence of FN and neutropenia in the clinical setting in patients receiving docetaxel for mCRPC is higher than previously reported and high enough to consider primary prophylaxis with granulocyte colony stimulating factors in high-risk groups. Age and multiple comorbidities were identified as risk factors.